跳至主要内容
临床试验/NCT02885168
NCT02885168已完成4 期

Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C

Central Hospital, Nancy, France0 个研究点目标入组 30 人开始时间: 2008年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
30
主要终点
Vascular reactivity measured with dose-response to phenylephrine

研究概览

简要总结

The purpose is to demonstrate that vasoreactivity of patients with septic shock evaluated with dose-response curve is diminished in septic shock and ameliorated by activated protein C (APC).

This amelioration is correlated to decrease of inflammation, decrease of reactive oxygen species (ROS) markers and increase of circulating catecholamines.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with septic shock as determined by standard criteria (including infection and severe infection)

排除标准

  • Pregnant women
  • Absence of signed informed consent. Due to gravity of medical situation of patients, inclusion will be possible after informed consent of a family member. As soon as possible, an informed consent will be obtained by patient
  • Contraindication to Xigris: evolutive internal bleeding , intracranial pathology, neoplasia or brain involvement, concomitant heparin therapy >= 15 IU/kg/h, known hemorrhagic diathesis except acute coagulopathy subsequent to sepsis, severe chronic liver disease, platelet count < 30000 x 10^6/L, high bleeding risk, known hypersensibility to drotrecogin alfa (activated), one of excipients or bovine thrombin

研究组 & 干预措施

Shock + Treatment

Experimental

Patients treated with activated protein C

干预措施: Recombinant Activated Protein C (Drug)

Shock + Treatment

Experimental

Patients treated with activated protein C

干预措施: Near-infrared spectroscopy (NIRS) (Device)

Shock + Treatment

Experimental

Patients treated with activated protein C

干预措施: Phenylephrine (Drug)

Shock + Treatment

Experimental

Patients treated with activated protein C

干预措施: Blood sample (Biological)

Shock

Other

Patients not treated with activated protein C

干预措施: Near-infrared spectroscopy (NIRS) (Device)

Shock

Other

Patients not treated with activated protein C

干预措施: Phenylephrine (Drug)

Shock

Other

Patients not treated with activated protein C

干预措施: Blood sample (Biological)

结局指标

主要结局

Vascular reactivity measured with dose-response to phenylephrine

时间窗: 24 hours

次要结局

未报告次要终点

研究者

发起方
Central Hospital, Nancy, France
申办方类型
Other
责任方
Sponsor

相似试验